MyFinsight
Home
Blog
About
Issuance of common stock
from the exercise of...
$9,226
Net cash provided by
financing activities
$8,476
(-99.88%↓ Y/Y)
Canceled cashflow
$750
Net change in cash,
cash equivalents,...
-$4,736,368
(-1709.24%↓ Y/Y)
Canceled cashflow
$8,476
Change in fair value of
warrant liabilities
$1,527,603
(2332.33%↑ Y/Y)
Other current assets
-$377,929
(-1405.51%↓ Y/Y)
Accounts payable and
accrued liabilities
$348,432
(-24.52%↓ Y/Y)
Stock-based compensation
$329,940
(111.23%↑ Y/Y)
Amortization expense
$157,541
(-50.00%↓ Y/Y)
Proceeds from exercises
of pre-funded...
-$750
(-186.11%↓ Y/Y)
Net cash used in
operating activities
-$4,707,516
(32.02%↑ Y/Y)
Effect of foreign
currency translation on...
-$37,328
(-762.90%↓ Y/Y)
Canceled cashflow
$2,741,445
Net loss
-$5,273,852
(27.55%↑ Y/Y)
Change in fair value of
derivative warrant...
-$1,548,227
Prepaid expenses
$626,882
(13.82%↑ Y/Y)
Back
Back
Cash Flow
Pasithea Therapeutics Corp. (KTTA)
Pasithea Therapeutics Corp. (KTTA)
source: myfinsight.com